Results 141 to 150 of about 8,134 (194)

A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]

, 2017
et al,, Yee, Derek
core   +1 more source

The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD. [PDF]

Nephrol Dial Transplant
Geertsema P, Bais T, Kuiken V, Knol MGE, Casteleijn NF, Vart P, Meijer E, Gansevoort RT.   +7 more
europepmc   +1 more source

急性非代償性心不全に対するトルバプタン治療レスポンダーの特徴：腎臓サイズ維持の重要性 [PDF]

, 2016
Toda, Hironobu
core  

Response to the Letter to the Editor Entitled "SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes". [PDF]

Kidney Int Rep
Uchiyama K.
europepmc   +1 more source

A small molecule stabilizer rescues the surface expression of nearly all missense variants in a GPCR. [PDF]

Nat Struct Mol Biol
Mighell TL, Lehner B.
europepmc   +1 more source

Long-Term Experience of Tolvaptan: Is Hepatotoxicity Still a Concern? [PDF]

Kidney360
Brown PA, Bubolic S, Laplante A, Jaeger T, Alam A.   +4 more
europepmc   +1 more source

Syndrome of inappropriate antidiuresis secondary to multiple myeloma: a case report and literature review. [PDF]

Front Oncol
Fan L, Ding T, Mao L, Wang Q, Ye H, Li Y, Zhang S, Ji L.   +7 more
europepmc   +1 more source

Dapagliflozin use in tolvaptan-treated patients with ADPKD: exploring renal outcomes in a retrospective study. [PDF]

Clin Kidney J
Nakajima R, Minatoguchi S, Umeda R, Koide S, Hasegawa M, Hayashi H, Tsuboi N.   +6 more
europepmc   +1 more source

Effectiveness and hepatic safety of short-term low-dose tolvaptan for severe hyponatremia: A retrospective comparative study. [PDF]

Medicine (Baltimore)
Uyar S, Kaplan Çayir M, Koca N.
europepmc   +1 more source